GLP-1 Drugs Beyond Weight Loss: What the Evidence Shows for the Heart, Kidneys and Brain

Drugs built for diabetes and weight loss are now approved to protect hearts and kidneys, and they are being tested against addiction and dementia. Some of those bets have paid off. One of the biggest just failed. Here is how to tell which is which.

The Spin

01 For heart and kidney disease, the evidence is strong and regulators have acted. Semaglutide cut major cardiovascular events by about 20% in people with obesity and existing heart disease (SELECT), and cut serious kidney events by 24% in people with type 2 diabetes and kidney disease (FLOW).

02 For the brain, the picture is mixed. In late 2025, two large Phase 3 trials found that oral semaglutide did not slow early Alzheimer’s disease, even though some biomarkers moved. Alcohol-use research looks promising but is still early.

03 The risks are real but mostly small. Stomach side effects are common. Pancreatitis and a rare optic-nerve condition called NAION are the safety questions regulators are watching. Supply is no longer the problem it was; price and coverage now are.

Why a weight-loss drug can affect the whole body

GLP-1 is a gut hormone released after eating. It helps the pancreas release insulin, slows the stomach, and signals fullness to the brain. Drugs that mimic it, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which also mimics a second hormone called GIP, were first approved for type 2 diabetes and then for obesity.

Two things make them look broader than “diet drugs.” First, GLP-1 receptors are found in the heart, kidneys, liver and brain, not just the gut and pancreas. Second, obesity itself drives heart failure, kidney damage, fatty liver and sleep apnea, so treating it can help all of them. Researchers still debate how much of the benefit comes from weight loss and how much from the drugs acting directly. The answer likely differs by organ.

The label “beyond weight loss” already has regulatory backing in several places. The FDA approved tirzepatide for severe obstructive sleep apnea in adults with obesity in December 2024, and approved semaglutide (Wegovy) for liver scarring from MASH in August 2025.

The heart: the strongest case

Evidence stage: Approved indications, large outcome trials.

The landmark result is SELECT, a trial of more than 17,000 adults with overweight or obesity and established cardiovascular disease, but without diabetes. Semaglutide 2.4 mg lowered the risk of major adverse cardiovascular events (heart attack, stroke or cardiovascular death) by about 20% compared with placebo. The benefit was clearest for heart attacks; the reduction in non-fatal stroke was smaller and less certain. People with diabetes had already shown benefit in earlier semaglutide trials, and oral semaglutide cut major events by 14% in a diabetes trial called SOUL.

Tirzepatide’s picture is newer. In SURPASS-CVOT, tirzepatide showed cardiovascular benefit in type 2 diabetes with established heart disease, but the comparison was against another GLP-1 drug (dulaglutide), not placebo. The trial that matters for people without diabetes, SURMOUNT-MMO, enrolls roughly 15,000 people and is not expected to report until late 2027. Until then, it is fair to say the strongest heart-attack-and-stroke data for obesity without diabetes belongs to semaglutide.

Heart failure is a second front. In SUMMIT, tirzepatide cut the risk of cardiovascular death or worsening heart failure by 38% in 731 people with obesity and heart failure with preserved ejection fraction (HFpEF), and improved symptoms. The semaglutide STEP-HFpEF trials (1,145 people) improved symptoms and exercise capacity but were not built to measure hospitalizations or deaths. Both are relatively small, and a large real-world analysis suggesting more than 40% lower risk of heart-failure hospitalization or death is observational, which means it cannot prove cause and effect.

The kidneys: approved for people with diabetes

Evidence stage: Approved for a defined group; unproven elsewhere.

In FLOW, 3,533 people with type 2 diabetes and chronic kidney disease received semaglutide 1 mg weekly or placebo on top of standard care. The trial was stopped early after interim results showed clear benefit: a 24% lower risk of a composite of kidney failure, major kidney decline, and kidney or cardiovascular death. That worked out to roughly 5 percentage points in absolute terms over three years. The FDA added this indication to Ozempic in January 2025.

The limits matter. FLOW enrolled people who already had both diabetes and kidney disease and were generally also receiving standard kidney-protective care. It does not show that GLP-1 drugs protect healthy kidneys, or that they help kidney disease in people without diabetes. For tirzepatide, the current kidney work is mostly mechanistic. A Phase 2 study called TREASURE-CKD, of about 140 people, is measuring kidney oxygenation on MRI, not kidney failure or survival.

The brain: one big disappointment, one open question

Evidence stage: Failed Phase 3 (Alzheimer’s); early clinical (addiction).

Alzheimer’s disease. Observational studies and animal work suggested GLP-1 drugs might protect neurons by calming inflammation and improving blood flow. Novo Nordisk tested that idea properly in EVOKE and EVOKE+, which enrolled 3,808 people aged 55 to 85 with early symptomatic Alzheimer’s. Oral semaglutide, given daily for two years, did not slow disease progression on the primary clinical measure in either trial. Some Alzheimer’s-related biomarkers improved by up to roughly 10%, but that did not translate into patients doing better. The one-year extension was cancelled.

This is a good example of the gap between biomarker and benefit that Spin Pharma often flags. The result answers one question (does oral semaglutide help people who already have symptoms?). It does not settle whether other GLP-1 drugs, earlier treatment, or longer use could help prevent dementia.

Alcohol and other addictions. GLP-1 receptors are present in the brain’s reward circuits, and people on these drugs often report less interest in alcohol. A 2026 meta-analysis found GLP-1 use was linked to a lower risk of an alcohol-use-disorder diagnosis, though not clearly to fewer alcohol-related hospitalizations. A 2026 randomized trial of semaglutide in moderate-to-heavy drinkers reported less drinking and fewer cravings, according to its lead researcher. Large observational studies also point to lower rates of opioid, cannabis and cocaine use disorders. These are encouraging, but the observational data are confounded, trials are small and short, and no GLP-1 drug is approved for any addiction.

Side effects and safety signals

Common: nausea, vomiting, diarrhea, constipation and abdominal pain. These are the most frequent reasons people stop, and they are usually worst when the dose is raised. In a head-to-head weight-loss trial (SURMOUNT-5), fewer people stopped tirzepatide than semaglutide because of side effects, about 3% versus 6%.

Pancreatitis. Inflammation of the pancreas is a known but uncommon risk. In 2025 the UK regulator (MHRA) strengthened warnings across the class after reviewing reports that included rare necrotising and fatal cases. Its advice: stop the drug if pancreatitis is suspected and use caution in people with a history of it. Reports are not the same as proof of cause, and several analyses have found no clear rise in risk.

Vision loss (NAION). NAION is a sudden, usually painless loss of vision in one eye caused by reduced blood flow to the optic nerve. The European Medicines Agency classed it as a “very rare” semaglutide side effect in 2025, and the UK regulator put the possible frequency at up to 1 in 10,000 people. A 2026 US Veterans Affairs study found a roughly twofold higher risk than with another diabetes drug class, but the absolute rate stayed low (about 0.3% over follow-up versus 0.13%). A May 2026 review by ophthalmology and neuro-ophthalmology societies found a possible two-fold relative increase in risk, no confirmed mechanism, and no support for routine eye exams before starting treatment. Some researchers argue part of the signal reflects reporting bias, but that analysis is a preprint that has not been peer reviewed. The FDA has been investigating. Anyone with sudden vision changes should seek urgent medical care.

Other issues: semaglutide and tirzepatide carry a warning about thyroid C-cell tumors based on rodent studies, with no clear confirmation in people. Weight lost on these drugs includes some lean mass, and weight generally returns when the drugs are stopped, which is why most are treated as long-term medicines.

Supply, price and access

The shortages that began in 2022 are over. The FDA declared the tirzepatide shortage resolved in late 2024, confirmed it in February 2025, and declared the semaglutide shortage over in early 2025. That ended the legal basis for mass compounding. Even so, compounded versions are still sold, and pharmacy trade press describes a continuing regulatory crackdown through 2026. The FDA has warned that people should not use a compounded drug when an approved one is available.

The bigger story is now cost and coverage. Under agreements announced in November 2025, the manufacturers cut cash prices through the government’s TrumpRx platform; in early 2026 listed prices started around $149 a month for the Wegovy pill, $199 for the Wegovy and Ozempic pens, and $299 for Zepbound, with higher doses costing more. The deals also set up Medicare coverage of obesity treatment for eligible people with a $50 monthly copay, scheduled for mid-2026. Eligibility rules are narrow, so readers should check current terms. Oral options are expanding too: an oral Wegovy and Lilly’s orforglipron (approved in 2026 for chronic weight management) give people a pill alternative to injections.

Where the evidence ends

Area	What is established	What is not
Heart attack and stroke	Semaglutide lowers events in people with obesity and heart disease (SELECT)	Tirzepatide in people without diabetes (due late 2027); benefit in people without existing disease
Heart failure	Tirzepatide cut death or worsening in obesity-related HFpEF; symptoms improve	Hospitalization and mortality data for semaglutide; other heart-failure types
Kidney	Semaglutide slows kidney disease in type 2 diabetes with CKD	People without diabetes; tirzepatide kidney outcomes
Alzheimer’s	Oral semaglutide did not slow early disease (EVOKE)	Prevention, earlier treatment, other drugs
Alcohol and addiction	Early trials and observational data are encouraging	No approval; long-term benefit; who responds
Safety	Gastrointestinal effects are common; pancreatitis and NAION are rare signals	Whether NAION is caused by the drugs; very long-term effects

Three habits help when reading the next GLP-1 headline. First, check whether the study was a randomized trial or an observational comparison. Second, ask whether the endpoint was something patients feel (events, symptoms, survival) or a lab marker. Third, look at who was enrolled; a result in people with diabetes and kidney disease does not automatically apply to everyone else.

Spin Pharma’s rule of thumb: GLP-1 drugs are now a proven cardiometabolic medicine with a rapidly widening, but uneven, evidence base. Not every organ will turn out to be a success story.

What to watch next

• SURMOUNT-MMO (tirzepatide cardiovascular outcomes in obesity without diabetes), expected late 2027.
• FDA decisions on NAION labeling and any further safety communications.
• Follow-up analyses from EVOKE on whether any Alzheimer’s subgroup benefits.
• Larger randomized trials of GLP-1 drugs for alcohol use disorder.
• Rollout and eligibility rules for Medicare obesity coverage.

Spin Pharma publishes general education and journalism. It does not diagnose, recommend treatments or recommend securities. Talk to a qualified clinician about your health. Company mentions are informational, and scientific progress is not a prediction of share-price performance.

Sources

• Full SELECT results, TCTMD summary of NEJM paper
• SURPASS-CVOT and SOUL summary, Diabetes on the Net
• SURMOUNT-MMO design and timing, Obesity journal commentary (PMC)
• SUMMIT results, Healio
• SUMMIT 731-patient trial summary, ACP Journal Club
• Real-world HFpEF emulation study, ACP summary
• FLOW and FDA approval, Healio
• FLOW trial details, PACE-CME
• TREASURE-CKD, ClinicalTrials.gov
• EVOKE and EVOKE+ results, Alzheimer Europe
• EVOKE at CTAD, NeurologyLive
• GLP-1 drugs and alcohol use disorder meta-analysis, 2026 (PMC)
• Semaglutide alcohol trial coverage, UC Health, July 2026
• Approved GLP-1 uses beyond diabetes and obesity (sleep apnea, MASH)
• MHRA pancreatitis warning summary, Hospital Healthcare
• MHRA NAION update, February 2026
• VA NAION cohort study, Optometry Times
• AAO and NANOS NAION review, May 2026
• NAION notoriety-bias preprint (not peer reviewed), medRxiv
• Compounded GLP-1 timeline, American Med Spa Association
• 2026 compounding crackdown, Drug Topics
• Does Medicare cover weight-loss drugs? AARP
• Medicare and pricing deal, HMP Global
• Orforglipron approval and GLP-1 formulary brief, Indian Health Service, August 2026